Buigues J, Vallejo J
J Clin Psychiatry. 1987 Feb;48(2):55-9.
The therapeutic response to phenelzine sulfate was evaluated during 6 months' treatment of 35 outpatients meeting DSM-III criteria for panic disorder or agoraphobia with panic attacks. The possible influence of nonspecific predictors of drug efficacy and some biochemical parameters were investigated. Therapeutic response was assessed on standardized rating scales. Agoraphobic patients showed a significantly higher frequency of panic attacks when compared to the subjects with uncomplicated panic disorder. Phenelzine treatment blocked panic attacks in 100% of the patients with panic disorder and in 94.7% of the agoraphobics. Anticipatory anxiety and avoidant behavior improved markedly, although not statistically significantly, in 73.6% of the agoraphobics.
对35名符合DSM-III惊恐障碍或伴有惊恐发作的广场恐惧症标准的门诊患者进行了为期6个月的硫酸苯乙肼治疗,并评估了治疗反应。研究了药物疗效的非特异性预测因素和一些生化参数的可能影响。通过标准化评分量表评估治疗反应。与单纯惊恐障碍患者相比,广场恐惧症患者的惊恐发作频率显著更高。硫酸苯乙肼治疗使100%的惊恐障碍患者和94.7%的广场恐惧症患者的惊恐发作得到控制。在73.6%的广场恐惧症患者中,预期性焦虑和回避行为有明显改善,尽管未达到统计学显著水平。